(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Brand names, (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Analogs
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Brand Names Mixture
- No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Chemical_Formula
C20H30O2
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate RX_link
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate fda sheet
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate msds (material safety sheet)
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Synthesis Reference
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Molecular Weight
302.456 g/mol
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Melting Point
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate H2O Solubility
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate State
Oily Liquid
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate LogP
6.23 +/- 0.48
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Dosage Forms
Capsule (usually in fish oil in a combination with DHA)
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Indication
EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Pharmacology
Eicosanoids are chemical messengers derived from 20-carbon polyunsaturated fatty acids that play critical roles in immune and inflammatory responses. Both 20-carbon omega-6 fatty acids (arachidonic acid) and 20-carbon omega-3 fatty acids (EPA) can be found in cell membranes. During an inflammatory response, arachidonic acid and EPA are metabolized by enzymes known as cyclooxygenases and lipoxygenases to form eicosanoids. Increasing omega-3 fatty acid intake increases the EPA content of cell membranes and decreases the arachidonic acid content, resulting in higher proportions of eicosanoids derived from EPA. Physiologic responses to arachidonic acid-derived eicosanoids differ from responses to EPA-derived eicosanoids. In general, eicosanoids derived from EPA are less potent inducers of inflammation, blood vessel constriction, and clotting than eicosanoids derived from arachidonic acid.
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Absorption
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate side effects and Toxicity
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Patient Information
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate Organisms Affected
No information avaliable
